Victory Capital Management Inc. Makes New $527,000 Investment in Savara Inc (NASDAQ:SVRA)

Victory Capital Management Inc. acquired a new position in shares of Savara Inc (NASDAQ:SVRA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 130,830 shares of the company’s stock, valued at approximately $527,000. Victory Capital Management Inc. owned about 0.09% of Savara at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Janus Henderson Group PLC boosted its holdings in Savara by 41.1% during the 1st quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock worth $12,754,000 after acquiring an additional 746,407 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Savara during the 4th quarter worth $9,683,000. Vanguard Group Inc. raised its stake in shares of Savara by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock worth $30,197,000 after purchasing an additional 148,673 shares during the period. Swiss National Bank bought a new stake in shares of Savara during the 1st quarter worth $732,000. Finally, Superstring Capital Management LP bought a new stake in shares of Savara during the 4th quarter worth $3,827,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Trading Down 3.2 %

Shares of Savara stock opened at $4.49 on Monday. Savara Inc has a 52-week low of $3.12 and a 52-week high of $5.70. The stock’s 50-day simple moving average is $4.38 and its 200 day simple moving average is $4.49. The stock has a market capitalization of $620.47 million, a P/E ratio of -12.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). As a group, research analysts anticipate that Savara Inc will post -0.44 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Oppenheimer lifted their target price on Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 26th. Guggenheim lifted their target price on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. JMP Securities reiterated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Monday, September 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Savara in a research note on Wednesday, August 14th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $11.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.